Efficacy and Safety of Cipros 10 Association on the Isolated Hypertriglyceridemia and Dyslipidemia Treatment

Last updated: February 15, 2024
Sponsor: EMS
Overall Status: Active - Recruiting

Phase

3

Condition

Hypertriglyceridemia

Dyslipidemia

Treatment

Crestor 10 mg

Cipros 10 association

Clinical Study ID

NCT03527069
EMS0617-CIPROS
  • Ages > 18
  • All Genders

Study Summary

The purpose of this study is to evaluate the efficacy of Cipros 10 association in the treatment of Dyslipidemia Treatment

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Participants of both sexes, aged 18 years or more;
  • Participants with the diagnosis of Dyslipidemia presentinf low or intermediatecardiovascular risk, according to the Brazilian Guidelines on Dyslipidemia andPrevention of Atherosclerosis;
  • Signed consent.

Exclusion

Exclusion Criteria:

  • Diagnosis of familial hypercholesterolemia and other genetic diseases;
  • Using medications that may interfere with the metabolism or serum levels oftriglycerides;
  • Any clinical and laboratory findings that, in the judgment of the investigator, mayinterfere with the safety of research participants;
  • Presence of concomitant cardiovascular disease, renal failure and hepatic Failure;
  • Decompensated diabetes;
  • Current smoking;
  • History hypersensitivity to the active ingredients used in the study;
  • Pregnancy or risk of pregnancy and lactating patients;
  • History of alcohol abuse or illicit drug use;
  • Participation in clinical trial in the year prior to this study.

Study Design

Total Participants: 298
Treatment Group(s): 2
Primary Treatment: Crestor 10 mg
Phase: 3
Study Start date:
January 29, 2021
Estimated Completion Date:
February 28, 2025

Connect with a study center

  • Allergisa

    Campinas, São Paulo
    Brazil

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.